.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Chinese Patent Office
Queensland Health
Baxter
Johnson and Johnson
Argus Health
Healthtrust
Teva
Cantor Fitzgerald
Citi

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 207960

« Back to Dashboard

NDA 207960 describes QUILLICHEW ER, which is a drug marketed by Pfizer Inc and is included in one NDA. It is available from one supplier. There are five patents protecting this drug. Additional details are available on the QUILLICHEW ER profile page.

The generic ingredient in QUILLICHEW ER is methylphenidate hydrochloride. There are thirty-one drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.

Summary for 207960

Tradename:1
Applicant:1
Ingredient:1
Patents:5
Therapeutic Class:Central Nervous System Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 207960

Suppliers and Packaging for NDA: 207960

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
QUILLICHEW ER methylphenidate hydrochloride TABLET, EXTENDED RELEASE, CHEWABLE;ORAL 207960 NDA NextWave Pharmaceuticals, Inc. 24478-120 24478-120-01 100 TABLET, CHEWABLE, EXTENDED RELEASE in 1 BOTTLE (24478-120-01)
QUILLICHEW ER methylphenidate hydrochloride TABLET, EXTENDED RELEASE, CHEWABLE;ORAL 207960 NDA NextWave Pharmaceuticals, Inc. 24478-130 24478-130-01 100 TABLET, CHEWABLE, EXTENDED RELEASE in 1 BOTTLE (24478-130-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE, CHEWABLE;ORALStrength20MG
Approval Date:Dec 4, 2015TE:RLD:Yes
Regulatory Exclusivity Expiration:Dec 4, 2018
Regulatory Exclusivity Use:NEW PRODUCT
Patent:► SubscribePatent Expiration:Mar 15, 2027Product Flag?YSubstance Flag?Delist Request?
Patent:► SubscribePatent Expiration:Feb 15, 2031Product Flag?YSubstance Flag?Delist Request?


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Johnson and Johnson
AstraZeneca
Novartis
Merck
Daiichi Sankyo
Covington
Argus Health
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot